Open AccessThe Lysosomal Diseases Testing Laboratory: A review of the past 47 years
Author(s) -
Wenger David A.,
Luzi Paola
Publication year - 2020
Publication title -
jimd reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.412
H-Index - 25
ISSN - 2192-8312
DOI - 10.1002/jmd2.12117
Subject(s) - metachromatic leukodystrophy , lysosomal storage disease , krabbe disease , lysosomal storage disorders , enzyme replacement therapy , leukodystrophy , gangliosidosis , sandhoff disease , fabry disease , medicine , cystinosis , disease , arylsulfatase a , niemann–pick disease , substrate reduction therapy , diagnostic test , pathology , bioinformatics , biology , pediatrics , enzyme , biochemistry , cystine , cysteine
Summary Lysosomal disorders are diseases that involve mutations in genes responsible for the coding of lysosomal enzymes, transport proteins, activator proteins and protein processing enzymes. These defects lead to the storage of specific metabolites within lysosomes resulting in a great variety of clinical features depending on the tissues with the storage, the storage products and the extent of the storage. The methods for rapidly diagnosing patients started in the late 1960's when the enzyme defects were identified eliminating the need for tissue biopsies. The first requests for diagnostic help in this laboratory came in 1973. In that year, patients with Krabbe disease and Niemann‐Pick type A were diagnosed. Since that time samples from about 62 000 individuals have been received for diagnostic studies, and 4900 diagnoses have been made. The largest number of diagnosed individuals had metachromatic leukodystrophy and Krabbe disease because of our research interest in leukodystrophies. A number of new disorders were identified and the primary defects in other disorders were clarified. With new methods for diagnosis, including newborn screening, molecular analysis, microarrays, there is still a need for biochemical confirmation before treatment is considered. With new treatments, including gene therapy, stem cell transplantation, enzyme replacement used alone or in combination becoming more available, the need for rapid, accurate diagnosis is critical.